Myeloablative therapy with autologous peripheral blood Extensive pretreatment has been identified as a signifistem cell (PBSC) rescue has become a widely used treatcant risk factor for failure of sufficient PBSC mobilizment modality for a variety of advanced malignancies. The ation. From published data and our own experience we use of PBSC as a stem cell source leads to more rapid defined pretreatment variables which render patients at engraftment and may also have less tumor cell contamirisk for not collecting at least 2.5 × 10 6 CD34-positive nation compared to bone marrow. [1] [2] [3] The number of CD34-cells per kg bodyweight (BW). These variables were previous unsuccessful PBSC mobilization trial, previous positive cells per kilogram body weight (BW) infused has large field radiotherapy, four or more cycles of myelobeen shown to correlate with neutrophil and platelet recovsuppressive chemotherapy regimens, and combinations ery kinetics. The reinfusion of more than 2.5 × 10 6 CD34-of extended field radiotherapy plus chemotherapy.
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Summary:
Myeloablative therapy with autologous peripheral blood Extensive pretreatment has been identified as a signifistem cell (PBSC) rescue has become a widely used treatcant risk factor for failure of sufficient PBSC mobilizment modality for a variety of advanced malignancies. The ation. From published data and our own experience we use of PBSC as a stem cell source leads to more rapid defined pretreatment variables which render patients at engraftment and may also have less tumor cell contamirisk for not collecting at least 2.5 × 10 6 CD34-positive nation compared to bone marrow. [1] [2] [3] The number of CD34-cells per kg bodyweight (BW). These variables were previous unsuccessful PBSC mobilization trial, previous positive cells per kilogram body weight (BW) infused has large field radiotherapy, four or more cycles of myelobeen shown to correlate with neutrophil and platelet recovsuppressive chemotherapy regimens, and combinations ery kinetics. The reinfusion of more than 2.5 × 10 6 CD34-of extended field radiotherapy plus chemotherapy.
positive cells/kg BW ensures an early and sustained hemaBased on these inclusion criteria we treated 19 patients topoietic recovery after myeloablative therapy. 4, 5 with disease-specific conventional-dose chemotherapy Mobilization protocols utilize hematopoietic growth facfollowed by sequential subcutaneous administration of tors such as granulocyte colony-stimulating factor (G-CSF) IL-3 (5 g/kg BW) for 5 consecutive days and G-CSF or granulocyte-macrophage colony-stimulating factor (10 g/kg) until PBSC collection or neutrophil recovery.
(GM-CSF) administered during steady-state hematopoiesis Patients were 10 males and nine females with a median or after cytotoxic chemotherapy, to increase the number of age of 43 years. Diagnoses were non-Hodgkin's lymcirculating hematopoietic progenitor cells. However, colphoma n ‫؍‬ 5, Hodgkin's disease n ‫؍‬ 2, multiple myellection of sufficient CD34-positive cells may not be possoma n ‫؍‬ 2, CML n ‫؍‬ 4, AML n ‫؍‬ 4 and testicular canible in all patients. It has been shown that pretreatment with cer n ‫؍‬ 2. Twelve patients had prior unsuccessful trial cytotoxic agents or radiotherapy adversely affects the yield of PBSC mobilization with chemotherapy followed by of CD34-positive cells. [6] [7] [8] On the other hand, age, sex, dis-G-CSF. Except for mobilization chemotherapy-related ease status and bone marrow involvement did not signifineutropenic fever, no major toxicities (WHO grade у2) cantly influence mobilization results in lymphoma patients.
9
were observed. Growth factors were well tolerated. ColThere is preclinical and preliminary clinical evidence lection of at least 2.5 ؋ 10 6 CD34-positive cells per kg that the combination of G-CSF or GM-CSF with inter-BW was possible in 11 out of 19 patients (58%). In five leukin-3 (IL-3) acts synergistically to mobilize PBSC in out of 12 patients with a previous unsuccessful trial of steady-state conditions or after cytotoxic therapy. 10 Geissler PBSC mobilization, the study regimen mobilized sufet al 11 described in six extensively pretreated lymphoma ficient CD34-positive cells. Nine patients went on to patients the successful mobilization of PBSC by sequential high-dose chemotherapy followed by autologous PBSC IL-3 (7 days) and G-CSF administration. In this series no transplantation. Prompt hematologic recovery was seen mobilization chemotherapy was given. Two patients had an in all of them. In conclusion, the sequential adminisunsuccessful trial of PBSC mobilization with G-CSF tration of IL-3 followed by G-CSF after conventionalalone. 11 D'Hondt et al 12 reported on the safe and successful dose chemotherapy allows successful PBSC collection in administration of IL-3 combined with G-CSF for PBSC the majority of extensively pretreated patients. mobilization. Keywords: PBSC; IL-3; G-CSF; transplantation; mobilIn the present study, we evaluated the sequential adminization istration of mobilization chemotherapy followed by IL-3 and G-CSF for efficiency of PBSC mobilization in extensively pretreated patients or in patients who had an unsuc- positive population in the peripheral blood dropped below treated at the University Hospital Mainz, were enrolled into 5/l. The cells were cryopreserved in cell culture medium, a prospective pilot study of sequential IL-3 and G-CSF which contained heparin 10 U/ml, dimethylsulfoxide 10%, administration after chemotherapy for PBSC collection.
penicillin 50 U/ml and streptomycin 0.05 mg/ml. The cell Inclusion criteria for patients entering the study were one or suspensions were frozen at a controlled rate in a computermore of the following: (1) previous large field radiotherapy; controlled freezing chamber (Cryoson, Schöllkrippen, (2) more than four previous myelosuppressive chemoGermany) and stored in liquid nitrogen at −196°C until therapy cycles; (3) previous combined extended field radioreinfusion. therapy and chemotherapy; and (4) previous unsuccessful
In the present study PBSC were mobilized by diseasetrial of PBSC mobilization. Characteristics of the patients specific chemotherapeutic treatment followed by daily subare shown in Table 1 . All patients gave informed consent cutaneous administration of 5 g/kg BW IL-3 (Sandoz, before entering the study.
Nürnberg, Germany) for 5 days followed by daily subcutaneous injections of 10 g/kg BW G-CSF until completion of leukapheresis. Progenitor harvest was started and perforMobilization procedure and PBSC collection med as mentioned above. Twelve out of 19 patients had an unsuccessful mobilization trial in the past, consisting of disease-specific chemotherapeutic treatment followed by daily subcutaneous adminisConditioning regimen and PBSC reinfusion tration of 5-10 g/kg BW G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) until completion of leukapher-
The pretransplant conditioning regimens consisted of total body irradiation (TBI; 14.4 Gy in 12 doses over 4 days) esis (Table 2) . WBC was monitored daily during hematopoietic recovery and CD34-positive cells were evaluated daily and cyclophosphamide (120 mg/kg) in one patient; busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) in one after passing the WBC nadir and recovering to a WBC of 1.0 × 10 9 /l. Leukapheresis procedures were generally perpatient; carmustin (300 mg/m Table 1 Pretreatment characteristics of patients mobilized with sequential administration of IL-3 and G-CSF Sex: M = male; F = female. Diagnosis: MM = multiple myeloma; HD = Hodgkin's disease; AML = acute myeloid leukemia; NHL = non-Hodgkin's lymphoma; lg = low grade; hg = high grade; CML = chronic myeloid leukemia. Remission status: PD = progressive disease; Rel. = relapse; PR = partial remission; CR = complete remission; CP = chronic phase; BC = blast crisis. Cytotoxic therapy: XRT = radiation therapy; MP = melphalan, prednisone; VAD = vincristine, adriamycin, dexamethasone; HDCy = high-dose cyclophosphamide; COPP/ABVD = cyclophosphamide, vincristine, procarbacine, prednisone, adriamycin, bleomycin, vinblastine, dacarbacine; DA = daunorubicin, cytosine arabinoside; AV = etoposide, cytosine arabinoside; DAV = daunorubicin, cytosine arabinoside, etoposide; HAM = high-dose cytosine arabinoside, mitoxantrone; COP = cyclophosphamide, vincristine, prednisone; PmMi = prednimustine, mitoxantrone; AraC = cytosine arabinoside; Ida = idarubicine; Amsa = amsacrine; CHOP = cyclophosphamide, adriamycin, vincristine, prednisone; CHOEP = cyclophosphamide, adriamycin, vincristine, etoposide, prednisone; PEB = cisplatinum, etoposide, bleomycin; PEI = cisplatin, etoposide, ifosfamide; IEV = ifosfamide, epiorubicin, etoposide; IFN = interferon-␣. Cytotoxic therapy: HDCy = high-dose cyclophosphamide; DAV = daunorubicin, cytosine arabinoside, etoposide; HAM = high-dose cytosine arabinoside, mitoxantrone; AraC = cytosine arabinoside; Ida = idarubicine; Amsa = amsacrine; CHOEP = cyclophosphamide, adriamycin, vincristine, etoposide, prednisone; PEI = cisplatin, etoposide, ifosfamide; IEV = ifosfamide, epirubicin, etoposide.
sine arabinoside (24 g/m 2 ), etoposide (1600 mg/kg) in three Colony growth was evaluated in semisolid medium as previously described. 13 In brief, mononuclear cells from patients; and carboplatin (2100 mg/m 2 ), etoposide (2250 mg/m 2 ) in one patient. Forty-eight hours after the last leukapheresis products were separated by Ficoll gradient centrifugation. Cells were suspended at a density of 5 × 10 3 , dose of chemotherapy, all of the cryopreserved apheresis products were thawed rapidly at the bedside and were rein-10 4 and 2 × 10 4 in culture medium containing 0.3% agar in a volume of 0.25 ml and plated in multiwell tissue culture fused via an indwelling central venous catheter. All patients received prophylactic oral antibiotic therapy with ofloxacin.
plates (Nunc, Wiesbaden, Germany). After solidification of the agar layer, a liquid overlayer of culture medium was Antibiotic combination therapy was administered for fever greater than 38.3°C, and amphotericin B was added for added to the culture plates containing hematopoietic growth factors. The final concentration of growth factors was as documented fungal infection or persistent fever. A platelet count greater than 20 × 10 9 /l was maintained by singlefollows: G-CSF 200 ng/ml; IL-3 50 ng/ml. At the end of a 14-day incubation period, the agar cultures were fixated donor platelet transfusions, and packed red blood cells were given when the hemoglobin was less than 8.5 g/dl. All with glutaraldehyde 2.5%, washed with distilled water for 4 h, transferred on to microscopic slides, dried at 40°C, blood products were leukocyte depleted and irradiated.
stained with May-Grünwald-Giemsa, and permanently mounted. Colony numbers were evaluated in such slides by Measurement of progenitor cell content light microscopy. The frequency of CFUs was calculated as follows: frequency = (CFU count/seeding density). To The percentage of cells that expressed the CD34 antigen was determined in whole blood or in a sample of the leuevaluate the total number of collected CFUs/kg BW the seeding density dependent optimal rate of CFUs was kapheresis product by direct immunofluorescence. Twenty l of the sample was incubated for 15 min at 4°C with divided by the sample Ficoll recovery multiplied by the total white cell count in the leukapheresis products divided fluorescence-labeled monoclonal antibodies against CD34 and CD45 (Immunotech, Hamburg, Germany). After lysis by BW. of the erythrocytes with isomolar ammonium chloride buffer for 10 min, the cells were resuspended in phosphateStatistical analysis buffered saline (PBS) that contained 0.2% (w/v) bovine serum albumin (BSA). The cells were analyzed by flow
The clinical and laboratory data of patients were analyzed cytometry (Coulter, Krefeld, Germany). We used a foraccording to standard statistical methods. Pearson correward-scatter vs CD45 fluorescence dot plot to discriminate lation was calculated between CD34-positive cells and CFU between the smallest lymphohematopoietic cell population content of leukapheresis products (GraphPad Software, San and erythrocyte debris. The CD34-positive cell population Diego, CA, USA). A significance level of P Ͻ 0.05 was was analyzed in a fluorescence-1 vs side-scatter characterchosen. The observed side-effects of the cytokine administration during the mobilization regimen are shown in Table 3 . The products divided by BW. Table 3 Frequency of adverse events of the mobilization regimen with sequential administration of chemotherapy, IL-3 and G-CSF. tericin B and was subsequently successfully transplanted without reactivation of fungal infection. One patient Table 4 shows the mobilization results according to developed a pectangina during a neutropenic fever episode. patient characteristics. All patients with extensive previous chemotherapy and a significant number of patients with PBSC collection previous radiotherapy mobilized sufficient CD34-positive Nineteen patients with a variety of hematologic malignancies were entered into the mobilization study. In 14 of Table 4 Success of PBSC mobilization by sequential administration of chemotherapy, IL-3, and G-CSF according to diagnosis, disease status, them a CD34-positive cell population of у5/l was The median number of CFU-GM collected in apheresis The median number of BFU-E mobilized was 3.5 (range cells. Twelve patients had undergone an unsuccessful mobigenitor mobilization by the sequential administration of ILlization trial previously. The study protocol was able to 3 and GM-CSF compared to GM-CSF alone. 14,15 Brugger mobilize sufficient CD34-positive cells for stem cell transet al 16 reported the use of chemotherapy followed by GMplantation in five of these patients. In addition to three leu-CSF with or without IL-3 for PBSC mobilization. They kemia patients, there was one patient with a germ cell found a significantly better CD34-positive cell collection in tumor and one patient with a high-grade NHL in this group. mildly to moderately pretreated patients who received the combination of IL-3 and GM-CSF compared to GM-CSF alone. D'Hondt et al 12 reported on the successful mobilization of eight patients who received sequential or simulEngraftment data taneous IL-3 and G-CSF following chemotherapy. Geissler So far, nine patients, including one patient with CML and et al 11 used IL-3 and G-CSF vs G-CSF alone without preone patient with AML, received high-dose chemotherapy ceding chemotherapy for PBSC mobilization in extensively followed by rescue with the collected PBSC. The median pretreated patients in an intrapatient comparison. They number of days to recover WBC Ͼ1000/l was 11 (range could demonstrate a significant better PBSC mobilization 9-15). Median number of days to platelet recovery after sequential IL-3 and G-CSF administration compared Ͼ20 000/l was 12 (range 9-27). The short time of bone with G-CSF alone. marrow recovery was reflected by the low need for RBC
Severity of adverse events
The cytokine combination of IL-3 and G-CSF was well (median 4, range 2-10 units packed RBC) or platelet tolerated in our patients and adverse reactions of the mobil-(median 6, range 2-9 single donor apheresis products) ization regimen were mainly chemotherapy related. No transfusions. The CML patient recovered with Ph-positive patient interrupted the mobilization treatment. As has been hematopoiesis. The AML patient had a relapse 2 months described by D'Hondt and others, the combination of IL-3 after autografting.
and G-CSF seems to be better tolerated than the combination of IL-3 and GM-CSF.
12,17
The sequential administration of IL-3 and G-CSF following chemotherapy allowed, in the majority of extensively pretreated patients investigated, the successful mobilization Discussion of sufficient PBSC, as shown by CD34-positive cell count. A number of patients with a previous unsuccessful trial of Collection of sufficient PBSC for safe rescue after mye-PBSC collection, were able to mobilize sufficient CD34-loablative therapy in heavily pretreated patients poses a positive cells for autografting, using IL-3 and otherwise major clinical problem. Based on literature data, the follownearly identical mobilization procedures. Engraftment in ing pretreatment conditions seem to pose an increased risk nine patients was rapid and sustained after high-dose therfor insufficient PBSC mobilization: previous large field apy. These data imply that sufficient numbers of committed irradiation; previous repeated myeloaplasiogenic therapy; as well as early progenitor cells are mobilized by the regiand combined previous chemotherapy and radiotherapy. 4, 7, 9 men used. In an attempt to confirm these risk factors we performed a
In the recent past, other cytokine combinations have been retrospective analysis of PBSC mobilization outcome at our tested for PBSC mobilization in heavily pretreated patients. center in 91 consecutive patients with a wide variety of Winter et al 18 described a synergistic effect of sequential diagnoses, pretreatment and disease status. Sixty-eight peradministration of GM-CSF and G-CSF on PBSC mobilizcent of patients mobilized more than 2.5 × 10 6 CD34-posiation. Moskowitz et al 19 reported on the use of the recombitive cells/kg BW by use of standard mobilization pronant human stem cell factor (rhSCF) (5-15 g/kg/day) and cedures (chemotherapy + G-CSF 5 g/kg BW s.c.).
Filgrastim (10 g/kg/day) compared to Filgrastim alone for Univariate logistic regression models revealed active and mobilization of PBSC in relapsed NHL patients. Heavily progressive disease status as the only statistically signifipretreated patients had a median 2.9 (0.09-13.3) × 10 6 /kg cant characteristic for mobilization failure (data BW CD34-positive cells after rhSCF plus Filgrastim unpublished). Because of the heterogeneity and the limited (n = 16) vs 1.4 (0.03-3.4) × 10 6 /kg BW after Filgrastim number of cases, no other variables showed a statistically alone (n = 5). 19 A prospective randomized clinical trial significant association with the probability of a successful comparing these two cytokine regimens after mobilization mobilization. However, none of five patients who chemotherapy in heavily pretreated NHL patients is curunderwent large field radiotherapy (mantle field, inverted y rently ongoing. field, large field abdominal irradiation) and only one of
In conclusion, the mobilization regimen with chemoseven patients with more than two previous myelosuppresstherapy followed by sequential administration of IL-3 and ive salvage chemotherapy cycles (Dexa-BEAM, IEV, G-CSF was safe and well tolerated. The mobilization of HAM, VIP, PEB) reached the minimum number of more than 2.5 × 10 6 /kg CD34-positive cells was possible 2.5 × 10 6 CD34-positive cells/kg BW, thus suggesting that in a significant number of patients, even after a previous these factors may play a role in the successful mobilization unsuccessful trial of stem cell mobilization. Engraftment of PBSC.
after PBSC transplantation was rapid and stable. In our We started a trial to collect sufficient PBSC in heavily view, the data warrant the randomized evaluation of an ILpretreated patients, using IL-3 in addition to G-CSF after 3 and G-CSF containing mobilization regimen compared to chemotherapy. Interleukin 3 has been used before for PBSC mobilization. Different groups reported the improved pro-G-CSF alone in extensively pretreated patients.
